By Counterforce Health Team in Uptravi (selexipag) —

How to Get Uptravi (Selexipag) Covered by Aetna (CVS Health) in Washington: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Uptravi (Selexipag) Covered by Aetna (CVS Health) in Washington

Aetna (CVS Health) requires prior authorization for Uptravi (selexipag) with documented WHO Group I PAH confirmed by right heart catheterization (mPAP >20 mmHg, PCWP ≤15 mmHg), WHO functional class II-IV, and step therapy showing failure of at least one ERA or PDE-5 inhibitor. Submit via pulmonologist/cardiologist using Aetna's PAH precertification form with hemodynamic data, 6-minute walk test results, and prior therapy documentation. Standard approval takes 30-45 days; expedited decisions within 72 hours for urgent cases. If denied, Washington residents have 180 days to appeal internally, then can request binding external review through the state's Independent Review Organization (IRO) process.

First step today: Call Aetna member services (number on your ID card) to request the PAH precertification form and confirm your formulary tier.

Table of Contents

  1. Who Should Use This Guide
  2. Member & Plan Basics
  3. Clinical Criteria for Uptravi Coverage
  4. Coding and Documentation Requirements
  5. Documentation Packet Essentials
  6. Submission Process
  7. CVS Specialty Pharmacy Enrollment
  8. After Submission: What to Expect
  9. Appeals Process in Washington
  10. Common Denial Reasons & Solutions
  11. Cost Assistance Options
  12. Frequently Asked Questions

Who Should Use This Guide

This guide is designed for Washington state residents with Aetna (CVS Health) coverage who need Uptravi (selexipag) for pulmonary arterial hypertension (PAH). You'll find this most helpful if you:

  • Have been diagnosed with WHO Group I PAH by a pulmonologist or cardiologist
  • Are currently on or have tried other PAH medications without adequate response
  • Face coverage challenges due to Uptravi's specialty tier status (~$9,000-$25,000 monthly retail cost)
  • Need to understand Washington's specific appeal rights and external review process

Expected outcome: With proper documentation, most clinically appropriate Uptravi requests get approved. If initially denied, Washington's robust appeal process—including binding external review—offers strong patient protections.

Member & Plan Basics

Coverage Verification Steps

  1. Check active coverage: Call Aetna member services (number on your ID card, typically 1-866-212-2851) to confirm your plan is active and includes prescription benefits
  2. Identify plan type: Determine if you have a commercial plan, Medicare Advantage, or Medicaid managed care—requirements may vary slightly
  3. Confirm specialty pharmacy requirement: Aetna typically requires CVS Specialty for Uptravi dispensing
  4. Review deductible status: High-deductible plans may require meeting deductible before coverage kicks in
Note: Self-funded employer plans may have different appeal rights under ERISA rather than Washington state law. Verify with your HR department.

Clinical Criteria for Uptravi Coverage

Aetna follows Clinical Policy Bulletin 0184 for PAH medications. Key requirements include:

Primary Diagnosis Requirements

  • WHO Group I PAH confirmed by right heart catheterization
  • Mean pulmonary artery pressure (mPAP) >20 mmHg at rest
  • Pulmonary capillary wedge pressure (PCWP) ≤15 mmHg
  • Pulmonary vascular resistance (PVR) >2 Wood units
  • WHO functional class II, III, or IV symptoms

Step Therapy Requirements

Documented inadequate response, intolerance, or contraindications to:

  • At least one endothelin receptor antagonist (ERA) like ambrisentan or bosentan, OR
  • One PDE-5 inhibitor such as sildenafil or tadalafil
  • Trial duration typically ≥60 days with objective measures of failure

Prescriber Requirements

  • Pulmonologist or cardiologist
  • Experience managing PAH patients
  • Ongoing monitoring plan for titration and side effects

Coding and Documentation Requirements

ICD-10 Codes for PAH

  • I27.0 - Primary pulmonary hypertension (idiopathic/heritable PAH)
  • I27.21 - Secondary pulmonary arterial hypertension (associated with connective tissue disease, HIV, portal hypertension, congenital heart disease)
  • I27.81 - Cor pulmonale (if right heart failure present)

Avoid using: I27.24 (chronic thromboembolic PH - WHO Group 4) or Group 2-5 codes, as Uptravi targets precapillary PAH only.

Additional Billing Considerations

  • Document WHO functional class explicitly in clinical notes
  • Include objective measures: 6-minute walk test distance, echocardiogram findings
  • Note any hospitalizations or emergency visits related to PAH progression

Documentation Packet Essentials

Core Clinical Documentation

  1. Right heart catheterization report (within 12 months, preferably recent)
  2. Echocardiogram showing right heart strain/enlargement
  3. 6-minute walk test results demonstrating exercise limitation
  4. Complete medication history with specific drugs, doses, durations, and reasons for discontinuation
  5. Current functional assessment with WHO class determination

Medical Necessity Letter Components

Your specialist should include these elements in their letter:

  • Patient demographics and Aetna member ID
  • Specific PAH diagnosis with WHO Group I confirmation
  • Hemodynamic data meeting Aetna's criteria
  • Functional class with objective supporting evidence
  • Detailed prior therapy history and outcomes
  • Clinical rationale for Uptravi specifically
  • Treatment goals and monitoring plan
  • Reference to FDA approval and PAH guidelines
Clinician Tip: Quote Aetna's Clinical Policy Bulletin criteria verbatim in your letter, then demonstrate how the patient meets each requirement with specific data points.

Submission Process

Required Forms

Submission Methods

  1. Availity Provider Portal (preferred for fastest processing)
  2. Fax: Check your denial letter or call for current fax number
  3. Mail: Include tracking for paper submissions

Timeline Expectations

  • Standard review: 30-45 days
  • Expedited review: 72 hours for urgent medical situations
  • Auto-approval: If Aetna misses federal decision deadlines

CVS Specialty Pharmacy Enrollment

Once prior authorization is approved, Aetna requires CVS Specialty for Uptravi dispensing:

  1. Enrollment: Your prescriber initiates enrollment through CVS Specialty (1-800-237-2767)
  2. Patient intake: CVS contacts you to verify insurance, address, and preferred delivery schedule
  3. Medication delivery: Typically 3-5 business days after enrollment
  4. Ongoing support: CVS provides refill reminders and clinical monitoring

Janssen CarePath Support

Consider enrolling in Janssen's PAH Companion program for additional PA support and patient resources.

After Submission: What to Expect

Tracking Your Request

  • Record confirmation numbers from all submissions
  • Check status weekly through Availity portal or member services
  • Document all communications with dates and reference numbers

Potential Outcomes

  • Approval: Coverage begins immediately; proceed with CVS Specialty enrollment
  • Partial approval: May include quantity limits or step therapy requirements
  • Denial: Review reasons carefully and prepare appeal strategy

Appeals Process in Washington

Washington state provides robust patient protections for insurance denials. Here's your step-by-step appeal pathway:

Internal Appeals (Required First Step)

  • Timeline: 180 calendar days from denial notice date
  • Level 1: Submit appeal with additional clinical evidence
  • Level 2: If Level 1 denied, file within 60 days of Level 1 decision
  • Decision timeframe: 30 days for standard appeals, 72 hours for expedited

External Review (Independent Review Organization)

If internal appeals fail, Washington offers binding external review:

  • Timeline: 120 days from final internal denial
  • Process: File through Washington State Office of the Insurance Commissioner
  • Contact: 1-800-562-6900 or insurance.wa.gov
  • Cost: Free to patients
  • Decision: Binding on Aetna if overturned

Expedited Appeals

For urgent situations where delay could harm your health:

  • Emphasize clinical urgency in all communications
  • Request peer-to-peer review with medical director
  • Document progressive symptoms or hospitalizations
From our advocates: We've seen Washington patients successfully overturn Aetna denials by emphasizing objective disease progression (declining 6-minute walk distances, worsening functional class) and including recent peer-reviewed studies supporting Uptravi's role in combination PAH therapy. The key is connecting clinical deterioration to the specific need for prostacyclin pathway activation.

Common Denial Reasons & Solutions

Denial Reason Solution Strategy Required Documentation
Insufficient PAH confirmation Submit complete hemodynamic data Right heart cath report with all pressure measurements
Missing functional class documentation Provide objective functional assessment 6-minute walk test, WHO class determination, symptom diary
Step therapy not met Document prior therapy failures Medication history with specific outcomes, side effects, contraindications
Non-formulary status Request formulary exception Medical necessity letter explaining why alternatives are inappropriate
Quantity limits exceeded Justify dosing requirements Titration schedule, current dose rationale, monitoring plan

Cost Assistance Options

Patient Support Programs

  • Janssen CarePath: Copay assistance and free drug programs for eligible patients
  • Patient Advocate Foundation: Grants for medication costs
  • HealthWell Foundation: Disease-specific assistance programs

Washington State Resources

  • Apple Health (Medicaid): May cover Uptravi with prior authorization
  • Washington Prescription Drug Program: Discount programs for eligible residents

Frequently Asked Questions

How long does Aetna prior authorization take for Uptravi in Washington? Standard reviews take 30-45 days, while expedited reviews for urgent cases are decided within 72 hours.

What if Uptravi is non-formulary on my plan? Request a formulary exception with medical necessity documentation showing why formulary alternatives are inappropriate for your specific case.

Can I appeal if I've been stable on Uptravi and Aetna suddenly denies coverage? Yes. Document your current stability and argue that discontinuation would cause clinical deterioration. Washington's continuity of care protections may apply.

Does step therapy apply if I tried medications in another state? Yes. Provide documentation of prior therapies regardless of where you received them. Out-of-state medical records are valid evidence.

How successful are appeals in Washington? Washington's external review process has historically favorable outcomes for patients, with many specialty drug denials overturned when clinical necessity is well-documented.

What if my employer plan is self-funded? Self-funded plans fall under federal ERISA law rather than Washington state protections. Contact the U.S. Department of Labor for ERISA appeal guidance.

At Counterforce Health, we help patients, clinicians, and specialty pharmacies turn insurance denials into targeted, evidence-backed appeals. Our platform analyzes denial letters, identifies the specific basis for rejection, and drafts point-by-point rebuttals using the right clinical evidence and payer-specific requirements. For complex cases like PAH medications, having the right documentation strategy can make the difference between approval and denial.

Whether you're facing your first prior authorization or appealing a denial, remember that persistence and proper documentation are key. Washington's strong consumer protections mean you have multiple pathways to coverage—use them.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies and requirements can change. Always verify current requirements with your insurer and consult with your healthcare provider for medical decisions. For personalized help with your specific situation, contact Counterforce Health or the Washington State Office of the Insurance Commissioner at 1-800-562-6900.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.